Diana Nazemian-Pour Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Abstracts this author is presenting:

• Nivolumab vs investigator’s choice (IC) for platinum-refractory recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; checkmate 141): Outcomes in first-line R/M patients and updated safety and efficacy — Poster Session 1
• Nivolumab vs Investigator’s Choice (IC) in patients with Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): efficacy and safety in checkMate 141 by Prior cetuximab use — Poster Session 1
• Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN) — Poster Session 1